THRβ-Selective Thyroid Hormone Analog Structure for Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing thyroid hormone analogs, such as T3, lack selectivity for thyroid hormone receptor β (THRβ), leading to side effects like cardiac arrhythmia and decreased muscle and bone volume due to binding to THRα, making it difficult to effectively combat obesity without serious side effects.
Innovation Solution
Design of novel THRβ-selective thyroid hormone analogs with specific structural features, including hydrophobic isopropyl and benzyl groups at the 3' position of the phenol moiety, aromatic rings for hydrophobic interactions, and bulky substituents like trifluoromethyl groups to enhance affinity and rigidity, represented by Formula (1).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T3 is used to activate lipid metabolism in the liver and adipose tissue through THRβ binding, then obesity treatment effectiveness is improved, but side effects occur due to lack of selectivity and binding to THRα
Solution Approach 1:
The patent applies local quality by introducing specific substituents at particular positions on the T3 molecular structure. The 3,5-dimethyl substituents are positioned to fix aromatic rings in a perpendicular arrangement, while the 3' position hydrophobic groups (isopropyl, benzyl, or naphthylmethyl) are strategically placed to interact with THRβ's hydrophobic region. This localized structural modification creates selective affinity for THRβ without compromising the essential thyroid hormone activity, thereby treating obesity effectively while avoiding THRα-mediated side effects.
2Adaptability or versatility
If GC-1 is developed as a THRβ-selective analog with 10-fold lower affinity for THRα, then selectivity is improved, but clinical trials were ended after phase 1
Solution Approach 1:
The patent applies parameter changes by systematically varying the hydrophobic substituent parameters at the 3' position of the phenol moiety. Different groups (isopropyl, benzyl, naphthylmethyl) with varying hydrophobicity and steric properties are introduced to optimize the balance between THRβ affinity and THRα selectivity. This parameter optimization aims to achieve sufficient receptor selectivity while maintaining adequate potency and safety profile for clinical advancement, addressing the limitations that halted GC-1 development.
3Strength
If hydrophobic groups are introduced at the 3' position to improve THRβ affinity, then binding affinity is improved, but molecular complexity increases
Solution Approach 1:
The patent applies composite materials by combining the core T3 molecular framework with additional hydrophobic substituent components. The molecule consists of the essential thyroid hormone structure复合ed with specific hydrophobic groups (isopropyl, benzyl, or naphthylmethyl) at the 3' position. This composite structure leverages the known biological activity of T3 while adding hydrophobic interactions to enhance THRβ binding affinity, achieving improved potency through structural composition rather than complete molecular redesign.
Data Source
Figure 1A~1C
Figure 2~3
Figure 4A~4C
AI summary
Provided is a compound useful as a thyroid hormone receptor β-selective thyroid hormone analog. A compound represented by Formula (1), a salt thereof, or a solvate thereof is provided.